Investment by Advent in the minority ownership of Felix confirmed
Advent International Acquires Minority Stake in Leading Global Animal Pharma Player
In a significant move, Advent International, a leading global private equity investor, has announced the acquisition of a minority stake in Felix Pharmaceuticals Pvt Ltd, a renowned player in the Gx animal pharmaceutical sector.
The deal, detailed on the Advent International website, saw the advisory team, led by Michael Coyle, provide comprehensive legal advice and support. The team included tax partner David Kilty and senior associate Nicola Cavey from Arthur Cox LLP, focusing on Tax matters. Colin Kavanagh, specialising in Life Sciences, was also part of the team.
Simon Breen and Robert Byrne, experts in Competition and Regulated Markets, were also part of the advisory team. The Corporate and M&A department was represented by Tim Gleeson, Daire Cassidy, Glyn McCormack, and Sondos Siiddiqi.
The specifics of the minority stake acquisition and the details of the deal are laid out on the Advent International website. The fact that Felix Pharmaceuticals Pvt Ltd is a leading global Gx animal pharma player is reiterated on the same platform.
Advent International's role as the investor in this deal is also clearly stated on their website. It is worth noting that no other law firms or individual advisors have been explicitly named as advising Advent on this particular Felix Pharmaceuticals investment, apart from Arthur Cox LLP and the key team members mentioned above.
The advisory team's work encompassed the Corporate and M&A, Tax, Competition and Regulated Markets, and Life Sciences aspects of the deal. For more detailed information about this acquisition, visitors are encouraged to visit the Advent International website.
This strategic investment is expected to bolster Advent International's portfolio in the pharmaceutical sector and further cement its position as a leading global private equity investor.
- The acquisition of a minor stake in Felix Pharmaceuticals Pvt Ltd by Advent International, a recognized private equity firm in finance, is expected to strengthen their portfolio in the pharmaceutical sector.
- This strategic investment by Advent International, a renowned player in private equity, signifies a significant move in the finance sector, as it reinforces their position as a leading global private equity investor in the pharmaceutical sector.
